44 Hartwell Ave
About Alloy Therapeutics
Alloy Therapeutics is a biotechnology ecosystem company empowering the global scientific community to make better medicines together. Through a community of partners, we democratize access to tools, technologies, services, and company creation capabilities that are foundational for discovering and developing therapeutic biologics. We provide affordable, non-exclusive access to the entire drug discovery community from academic scientists, small and medium biotech, to the largest biopharma.
Our lead offering, the ATX-Gx™ platform, is a human therapeutic antibody discovery platform consisting of a growing suite of proprietary transgenic mice strains.
Founded in 2017 and privately funded by visionary investors, we are headquartered in Boston, MA with European labs in Cambridge, UK.
As a reflection of our relentless commitment to the scientific community, Alloy reinvests 100% of its revenue in innovation and access to innovation.
5 articles with Alloy Therapeutics
Alloy Therapeutics Ecosystem Offerings Go Intracellular Through Collaboration with Sudhir Agrawal in Genetic Medicines
Alloy Therapeutics, a biotechnology ecosystem company, announced a collaboration and licensing agreement with Sudhir Agrawal’s Arnay Sciences to advance new RNA-based drug discovery platforms.
Tegmine Therapeutics Announces Collaboration with Alloy Therapeutics to Advance Solid Tumor Treatment
Tegmine Therapeutics today announced an investment from Alloy Therapeutics and a collaboration to accelerate the development of antibody therapeutics that target proteins carrying cancer-associated glycan post-translational modifications.
Mytide Therapeutics Raises $7 Million Series A Round to Transform Peptide Manufacturing with Machine Learning
Mytide Therapeutics, a company transforming peptide manufacturing with predictive analytics and machine learning, has raised $7 million in Series A financing.
Champions Oncology Announces a Partnership with Alloy Therapeutics to Develop Therapeutic Monoclonal Antibodies for Use in ADC Programs
Champions Oncology, Inc. announced today a therapeutic development partnership with Alloy Therapeutics.
Alloy Therapeutics Acquires deepCDR Biologics to Bring Bioinformatics and Machine Learning to its Antibody Discovery Offering
Alloy Therapeutics, a biotechnology ecosystem company, announced it has acquired deepCDR Biologics, a Basel, Switzerland-based developer of deep learning technology for antibody discovery and optimization.